(Q43848092)

27 November 2017

title

Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients (English)

1 reference

27 November 2017

1 reference

Jacobson P

1

1 reference

27 November 2017

Ng J

2

1 reference

27 November 2017

Ratanatharathorn V

3

1 reference

27 November 2017

Uberti J

4

1 reference

27 November 2017

Brundage RC

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Bone Marrow Transplantation

27 November 2017

published in

1 reference

27 November 2017

volume

28

1 reference

27 November 2017

issue

8

1 reference

27 November 2017

page(s)

753-758

1 reference

Clinical pharmacokinetics of tacrolimus

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

Practical considerations in the use of tacrolimus for allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

A reversible posterior leukoencephalopathy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

Bone-marrow transplantation (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

Tacrolimus clearance is age-dependent within the pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

Tacrolimus pharmacokinetics in BMT patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

Dysarthria and apraxia of speech associated with FK-506 (tacrolimus).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

In vitro generation of tacrolimus metabolites and their detection in whole blood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703224

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703224

1 reference

Dimensions Publication ID

27 November 2017

1040636934

0 references

1 reference